ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?
Novel Treatments, Medical Community, Diagnosis and Treatment, Clinical Research, Updates from Conferences, Entities of Cancer Our MBClife Novel Treatments, Medical Community, Diagnosis and Treatment, Clinical Research, Updates from Conferences, Entities of Cancer Our MBClife

ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?

Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.

Read More
ASCO 2022: When the Dust Settles, Will ADCs Change MBC?
Novel Treatments, Clinical Research, Medical Community, Entities of Cancer, Diagnosis and Treatment, Difficult to Treat, Updates from Conferences Our MBClife Novel Treatments, Clinical Research, Medical Community, Entities of Cancer, Diagnosis and Treatment, Difficult to Treat, Updates from Conferences Our MBClife

ASCO 2022: When the Dust Settles, Will ADCs Change MBC?

While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.

Read More
ER Progression and Resistance: Causes, Consequences, and Hope
Novel Treatments, Obstacles to Better Outcomes, Medical Community, Entities of Cancer, Difficult to Treat, Clinical Research, Precision Oncology, MBC Imaging and Profiling, Translational Research, Basic Science, Diagnosis and Treatment, Patient Reported Outcomes and Out of the Box Treatment Options Our MBClife Novel Treatments, Obstacles to Better Outcomes, Medical Community, Entities of Cancer, Difficult to Treat, Clinical Research, Precision Oncology, MBC Imaging and Profiling, Translational Research, Basic Science, Diagnosis and Treatment, Patient Reported Outcomes and Out of the Box Treatment Options Our MBClife

ER Progression and Resistance: Causes, Consequences, and Hope

Endocrine therapy is an effective way to treat hormone-sensitive breast cancers, but de novo and acquired resistance to this treatment remains a major challenge. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance.

Read More
Dr. Priya Kumthekar: Glimpses of Hope for Leptomeningeal Metastases
Novel Treatments, Obstacles to Better Outcomes, Medical Community, Entities of Cancer, MBC Imaging and Profiling, Radiation Therapy, Difficult to Treat Our MBClife Novel Treatments, Obstacles to Better Outcomes, Medical Community, Entities of Cancer, MBC Imaging and Profiling, Radiation Therapy, Difficult to Treat Our MBClife

Dr. Priya Kumthekar: Glimpses of Hope for Leptomeningeal Metastases

Co-hosts Victoria Goldberg and Dr. Paula Jayne sit down with neuro-oncologist Dr. Priya Kumthekar to talk about leptomeningeal metastases: what they are, how are they treated, and what research is upcoming, including a discussion on ANGled, the new Phase 3 trial for MBC patients newly diagnosed with leptomeningeal metastases.

Read More